GlassScriptPhysician profile
Dino D Klisovic
NPI 1477644573
$20,986.77
in general payments reported to CMS, 2019-2025
19 companies · $1,113 in 2025
The $1,113 reported for 2025 was more than what 76% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,150 · 2020: $2,441 · 2021: $4,799 · 2022: $7,693 · 2023: $635 · 2024: $1,156 · 2025: $1,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,805 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,805.23 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $17,476.23 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $1,003.98 | 2022-2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $722.18 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $489.12 | 2023-2025 | Vabysmo |
| Alimera Sciences, INC. | $291.92 | 2019-2024 | Iluvien, Yutiq |
| Apellis Pharmaceuticals, INC. | $225.80 | 2023-2025 | Syfovre |
| Ani Pharmaceuticals, INC. | $154.45 | 2024-2025 | Yutiq, Iluvien, Purified Cortrophin Gel |
| Abbvie INC. | $146.67 | 2023-2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $74.07 | 2020-2021 | |
| Astellas Pharma US INC | $67.13 | 2025 | Izervay |
| Allergan, INC. | $62.18 | 2019-2020 | |
| Sandoz INC. | $61.06 | 2024 | Cimerli |
| Bausch & Lomb Americas INC. | $53.83 | 2022-2023 | Xipere, Retisert, Visudyne |
| Horizon Therapeutics Plc | $46.28 | 2022 | |
| Biotissue Holdings INC. | $30.17 | 2022-2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $29.93 | 2023 | |
| Coherus Oncology, INC. | $20.08 | 2024 | |
| Novartis Pharmaceuticals Corporation | $16.43 | 2020 | |
| Eyepoint US, INC. | $15.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$629,241.24 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dino Klisovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.